Compare Mesoblast Limited (MESO) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vital Farms Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Vital Farms Inc trades at $13.29 (market cap $590.45M). The key difference: Mesoblast Limited is far larger — about 3.7× Vital Farms Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| MESO | VITL | |
|---|---|---|
Market Cap | $2.17B | $590.45M |
Sector | Technology | Consumer Staples |
52-Week High | $20.96 | $52.41 |
52-Week Low | $12.88 | $8.28 |
Enterprise Value | $2.17B | $593.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Vital Farms (VITL) trades at $13.76, up 1.55% with a bullish technical signal from moving averages. The company shows solid profitability with 6.1% net margin and 15.44% ROE, though recent earnings missed expectations in two of the last three quarters. Analyst consensus is positive with 56% buy ratings and a $13.50 price target, while news highlights declining short interest and ongoing class action lawsuits.
The stock presents a mixed outlook with strong fundamentals offset by legal risks and earnings volatility. Valuation appears reasonable with P/E of 13.02 and P/S of 0.79, but investors should weigh the class action litigation's potential impact against the company's operational strength in the natural foods sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
